Lipids in Health and Disease最新文献

{"title":"Correction: Dyslipidemia is associated with abdominal fat depots but not with bone mineral density and muscle fat infiltration.","authors":"Yuhang Yang, Yunjie Zhang, Jianrong Ji, Chao Song, Shiping Wang, Zaiqiang Liu, Xiaopeng Li, Yuanjiang Min, Xihao Tang, Jianxun Jiang, Guixuan Li, Mengyuan Fan, Qinfei Yang, Shizheng Hui, Jun Yuan, Guang Yang, Yandong Liu, Jun Li","doi":"10.1186/s12944-026-03082-2","DOIUrl":"10.1186/s12944-026-03082-2","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13663036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149182579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Dyslipidemia and metabolic syndrome in childhood-onset systemic lupus erythematosus: is it time to screen?","authors":"Sirin Nuntasri, Sirirat Charuvanij, Kraisoon Lomjansook, Puthita Saengpanit, Kwanjai Chotipanang, Maynart Sukharomana","doi":"10.1186/s12944-026-03061-7","DOIUrl":"10.1186/s12944-026-03061-7","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Association of fenofibrate therapy with cardiovascular events and mortality in diabetes patients with early-diagnosed hyperlipidemia.","authors":"Huidan Liu, Kan Wang, Yujie Ren, Xuefang Hu, Mian Li, Tiange Wang, Min Xu, Jieli Lu, Yufang Bi, Yu Xu","doi":"10.1186/s12944-026-03060-8","DOIUrl":"10.1186/s12944-026-03060-8","url":null,"abstract":"","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study.","authors":"Linus Haberbosch, Andrea Baessler, Ulrike de Ruiter, David Sinning, Julius L Katzmann, Stephanie Könemann, Ulrike Schatz, Knut Mai, Ursula Kassner, Thomas Bobbert","doi":"10.1186/s12944-026-03062-6","DOIUrl":"10.1186/s12944-026-03062-6","url":null,"abstract":"<p><strong>Background: </strong>Dyslipidaemia remains a leading cause of death in Germany despite an improving therapeutic landscape, with many patients not achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals. Bempedoic acid, an adenosine triphosphate citrate lyase inhibitor, is a recent addition to the therapeutic landscape with proven efficacy in randomised controlled trials; however, its use varies between centres. We aimed to assess the short-term, real-world effectiveness of bempedoic acid in lowering LDL-C levels in patients in Germany.</p><p><strong>Methods: </strong>This retrospective, observational study was conducted using data from patients with primary hypercholesterolaemia or mixed dyslipidaemia, collected before and approximately 3 months after initiating bempedoic acid in 7 specialised lipid outpatient clinics in Germany.</p><p><strong>Results: </strong>Data were analysed from a total of 641 patients, with a mean age (standard deviation [SD]) of 63.2 (11.3) years. The addition of bempedoic acid significantly reduced LDL-C levels from a mean of 133.6 mg/dL at baseline to 101.8 mg/dL after 3 months (p < 0.001). The mean within-patient LDL-C reduction was 31.8 mg/dL and the mean patient-level percentage change was -17.5%. Mean patient-level changes were -4.9% for HDL-C and -12.0% for total cholesterol; triglycerides did not change significantly. At 3 months, patients not receiving any lipid-lowering therapy (LLT) other than bempedoic acid had a mean patient-level LDL-C reduction of 27.1%; corresponding mean reductions were 23.7% with ezetimibe, 20.3% with PCSK9 inhibitor therapy, 9.0% with statin therapy and 6.1% with statin plus ezetimibe. Suspected adverse events were documented in 218/641 patients (34.0%), and 171/641 (26.7%) had discontinued bempedoic acid by follow-up. Myalgia was the most commonly reported adverse event in patients discontinuing treatment (75 cases).</p><p><strong>Conclusions: </strong>Findings from this real-world, multicentre study conducted in Germany show that bempedoic acid may present an effective treatment option for patients with hypercholesterolaemia who are already receiving LLT, in addition to being an effective option for patients not receiving/tolerating other LLTs. The magnitude of LDL-C reduction differed across background treatment strategies, while suspected adverse events and treatment discontinuation were common in this specialist-care cohort.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort.","authors":"Yan Chen, Kailing Xie, Ningkun Xiao, Haonan Ju, Qingzhi Zhou, Xin Zhao","doi":"10.1186/s12944-026-03048-4","DOIUrl":"10.1186/s12944-026-03048-4","url":null,"abstract":"<p><strong>Background: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is being increasingly recognized as a systemic cardiometabolic disorder rather than a liver-limited condition. However, the combined association of insulin resistance, systemic inflammation, and depressive symptoms with mortality remains unclear. Therefore, we developed an insulin resistance-systemic inflammation-psychological burden (ISP) index to evaluate its associations with all-cause mortality (ACM) and cardiovascular mortality (CVM).</p><p><strong>Methods: </strong>We analyzed data from 3,187 adults with MASLD in the 2005-2018 National Health and Nutrition Examination Survey. A random forest model based on mean decrease in accuracy was used to select representative markers from six insulin resistance surrogates and five systemic inflammation indices, which were combined with the PHQ-9 score to construct the ISP index. Weighted Kaplan-Meier and Cox analyses, restricted cubic splines, subgroup and sensitivity analyses, and interpretable machine learning with 5-fold cross-validation were performed.</p><p><strong>Results: </strong>During a median 8.25-year follow-up, 382 deaths occurred, including 114 cardiovascular deaths. The metabolic score for insulin resistance (METS-IR) and systemic inflammation response index (SIRI) were selected and combined with the PHQ-9 score to construct the ISP index. In fully adjusted Cox models, the highest ISP tertile was associated with higher risks of both ACM (HR = 1.63, 95% CI: 1.12-2.38) and CVM (HR = 2.88, 95% CI: 1.36‒6.10) compared with the lowest tertile. Eight ISP-based machine-learning models were internally evaluated using 5-fold cross-validation, with the GBM model yielding 10-year AUCs of 0.869 for ACM and 0.883 for CVM. SHAP analysis of the GBM model revealed that the ISP index ranked second in feature importance after age.</p><p><strong>Conclusions: </strong>The ISP index was positively associated with the risks of ACM and CVM among individuals with MASLD. However, because the ISP index was constructed and internally evaluated within the same sample, its apparent predictive performance may be optimistic owing to overfitting. Therefore, the ISP index requires external validation in larger, independent prospective cohorts.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13613631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic dysfunction-associated steatotic liver disease: pathogenic mechanisms and exercise-induced molecular adaptations.","authors":"Senlin Lei, Jiasheng Tao, Xiaoan Chen, Xianhui Li, Songwei Zhong","doi":"10.1186/s12944-026-03055-5","DOIUrl":"10.1186/s12944-026-03055-5","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic metabolic disorder that spans steatosis, steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Although hepatic lipid overload is a central pathological feature, MASLD progression is driven by interconnected disturbances in lipid handling, mitochondrial function, oxidative stress, immune-inflammatory activation, programmed cell death, autophagy-lysosomal homeostasis, and gut-liver communication. This review critically synthesizes current evidence on the pathogenic mechanisms of MASLD and the molecular adaptations induced by exercise. We discuss how impaired lipid storage, oxidation, export, and detoxification interact with organelle stress, macrophage activation, inflammasome and cell-death signaling, defective autophagic clearance, and bidirectional gut-liver inputs to promote hepatocellular injury and fibrogenesis. We further examine how exercise modality, intensity, dose, and timing influence MASLD, and summarize evidence suggesting that exercise may enhance lipid mobilization and fatty acid oxidation, improve mitochondrial and autophagic quality control, restrain inflammatory and programmed cell-death pathways, and reshape gut-liver axis function. Defining disease-stage- and phenotype-specific responses, together with reliable metabolic and molecular biomarkers, will be essential for translating exercise-induced adaptations into individualized MASLD management.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LDL hypercholesterolemia in children: genetic influence and response to lifestyle advice - follow-up of the Fr1dolin-trial.","authors":"Stefan Arens, Ursa Sustar, Karin Lange, Thomas Danne, Tadej Battelino, Urh Groselj, Olga Kordonouri","doi":"10.1186/s12944-026-03050-w","DOIUrl":"10.1186/s12944-026-03050-w","url":null,"abstract":"<p><strong>Background and aims: </strong>Although familial hypercholesterolemia (FH) is common and associated with significant cardiovascular morbidity, screening programs are scarce. Furthermore, the effectiveness of nutritional advice for parents on children's LDL cholesterol (LDL-C) levels is unclear, especially in FH versus non-FH hypercholesterolemia.</p><p><strong>Methods: </strong>In the Fr1dolin study, 367 of 14,513 children in Lower Saxony and Hamburg were positively screened for LDL hypercholesterolemia with an LDL-C > 135 mg/dl (> 3.5 mmol/l). The screening was considered positive if the first finding of hypercholesterolemia was confirmed in a second sample. These 367 children were invited to a follow-up examination including an extended lipid status, nutritional counseling and genetic analysis.</p><p><strong>Results: </strong>289 out of 367 screen-positive children (57.4% girls) were followed up for 12 months; 191 (66.1%) underwent genetic testing. Children with a FH-causing pathogenic or likely pathogenic variant (n = 40, 20.9%) had significantly higher LDL-C levels than children without a variant or with a variant of uncertain significance (p < 0.001). After the nutritional counselling and after 6 and 12 months of follow-up, LDL-C levels did not improve significantly (median LDL-C at baseline 142 mg/dl, and 140 mg/dl at 6 and 12 months follow-up, respectively).</p><p><strong>Conclusions: </strong>A population-based screening program detects LDL-hypercholesterolemia in up to 2.5% of children, with a significant proportion of them having FH genetic variants, supporting early detection. One-time nutritional advice had little effect on LDL-C in general, but particularly in FH, highlighting on the one hand need for structured lifestyle programs and on the other hand early genetic testing in population based FH screening.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13543629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triglyceride-glucose index as a cardiovascular risk marker: updated evidence, limitations, and future perspectives.","authors":"Mariia Cherska, Khrystyna Kukharchuk, Alexandr Ceasovschih, Victorita Sorodoc, Federica Fogacci, Tatyana Storozhenko, A M Abd El-Aty","doi":"10.1186/s12944-026-03036-8","DOIUrl":"10.1186/s12944-026-03036-8","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) remain the foremost cause of morbidity and mortality worldwide, accounting for a substantial burden on healthcare systems, economies, and society. Traditional risk factors do not fully explain residual cardiovascular risk, highlighting the role of insulin resistance (IR) as a key pathophysiological link between metabolic disorders and CVD. The triglyceride-glucose (TyG) index, a simple surrogate marker derived from fasting triglyceride and glucose levels, has emerged as a practical tool for assessing IR and cardiovascular risk. This review summarizes current evidence on the role of the TyG index in the development, progression, and prognosis of CVD. The TyG index reflects both hepatic and adipose tissue insulin resistance and has shown comparable or superior performance to traditional markers such as homeostatic model assessment of insulin resistance (HOMA-IR) but is easier to calculate and more feasible for routine clinical use. Large epidemiological and cohort studies have consistently demonstrated associations between elevated TyG values and increased risk of type 2 diabetes mellitus, coronary heart disease, myocardial infarction, stroke, peripheral arterial disease, and heart failure in both general and high-risk populations. Evidence suggests a dose-response relationship between TyG and cardiovascular outcomes, with higher TyG levels or adverse longitudinal trajectories conferring greater risk. Importantly, TyG has been linked to subclinical atherosclerosis, coronary microvascular dysfunction, and adverse cardiac remodeling, indicating its relevance in early disease stages. Sex-specific differences have been reported, with several studies showing stronger associations between TyG and cardiovascular risk in women. In addition, TyG has demonstrated prognostic value across diverse clinical settings, including acute and chronic coronary syndromes, myocardial infarction with nonobstructive coronary arteries, and heart failure. Despite these findings, the clinical implementation of the TyG index remains limited. Its incremental value beyond that of established risk models is inconsistent, and its predictive performance varies across populations, age groups, and ethnicities. Most available data are observational, with underrepresentation of non-Asian populations and younger individuals, and standardized clinical cutoff values have not been universally established. In conclusion, the TyG index is a simple, inexpensive, and widely accessible marker of insulin resistance with considerable potential for cardiovascular risk stratification. While current evidence supports its association with incident CVD, atherosclerotic burden, and adverse outcomes, further prospective, multiethnic studies are needed to define optimal thresholds, clarify its role alongside existing risk models, and determine whether TyG-guided strategies can improve clinical outcomes.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13640206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased LDL-C reduction with ezetimibe in ketogenic diet-induced hypercholesterolemia.","authors":"Jorge Gonzalez, Joshua Wageman, Laura Buchanan, Tro Kalayjian, Matthew Calkins, Erin Saner, Adrian Soto-Mota","doi":"10.1186/s12944-026-03034-w","DOIUrl":"10.1186/s12944-026-03034-w","url":null,"abstract":"<p><p>Several case reports and a meta-analysis have documented significant increases in cholesterol levels among individuals following a ketogenic diet. However, the mechanistic drivers of this phenotype remain incompletely understood. Here, we describe a retrospective case series of 14 patients with ketogenic diet-induced hypercholesterolemia who experienced larger-than-expected LDL-C reductions after ezetimibe therapy. In a subset of participants with available genetic data, no biallelic sitosterolemia-associated variants were identified in the loci assessed. We hypothesize that chronically low insulin levels may alter hepatic cholesterol homeostasis through changes in ACAT2-mediated cholesterol esterification and in NPC1L1/ABCG5/G8-mediated cholesterol handling. The magnitude of LDL-C reduction achieved with ezetimibe in this cohort suggests that altered cholesterol absorption may contribute importantly to this phenotype. This hypothesis-generating framework offers a plausible mechanistic explanation and supports further prospective study of precision lipid management in ketogenic diet-induced hypercholesterolemia.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13520245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"C-reactive protein-triglyceride-glucose index predicts postoperative delirium in older surgical patients: a retrospective cohort study.","authors":"Dandan Chang, Danyang Geng, Lulu Zhou, Huikai Yang, Yuxiang Song, Jingjing Ma, Weidong Mi, Miao Sun","doi":"10.1186/s12944-026-03037-7","DOIUrl":"10.1186/s12944-026-03037-7","url":null,"abstract":"<p><strong>Background: </strong>Postoperative delirium (POD) is a prevalent and serious complication in older surgical patients. The C-reactive protein-triglyceride-glucose index (CTI) is a recently developed composite marker that integrates both Insulin resistance (IR) and systemic inflammation. This study aimed to evaluate the association between CTI and POD in older surgical patients.</p><p><strong>Methods: </strong>Older surgical patients were retrospectively enrolled. The CTI was calculated and analyzed as both a continuous variable and a binary variable dichotomized at the optimal cut-off derived from receiver operating characteristic (ROC) analysis. Univariate and multivariable logistic regression models were constructed to examine the association between CTI and POD. Joint stratification by the TyG index and CRP was performed to delineate the synergistic contributions of IR and inflammation.</p><p><strong>Results: </strong>A total of 10,125 patients were included in the final analysis. The receiver operating characteristic (ROC) curve analysis determined the optimal cut-off value for CTI to be 7.57. As a binary variable, high CTI conferred significantly elevated odds of POD compared with low CTI in fully adjusted model (OR = 1.60, 95% CI: 1.28-2.00, P < 0.001). As a continuous variable, each unit increment in CTI was associated with a 35% increased risk of POD after full adjustment (OR = 1.38, 95% CI: 1.21-1.56, P < 0.001). Joint stratification further confirmed that patients with concurrently high TyG and high CRP exhibited the highest POD incidence.</p><p><strong>Conclusion: </strong>CTI may be a useful adjunct for preoperative risk stratification of POD in older surgical patients, but requires prospective validation.</p>","PeriodicalId":18073,"journal":{"name":"Lipids in Health and Disease","volume":"25 1","pages":""},"PeriodicalIF":6.9,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13589863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149008752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}